Ferdinando Varbella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6325893/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet, The, 2015, 385, 2465-2476.	6.3	1,043
2	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 997-1009.	13.9	334
3	Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet, The, 2014, 383, 2232-2237.	6.3	286
4	A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. Journal of the American College of Cardiology, 2012, 60, 2473-2480.	1.2	280
5	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	6.3	215
6	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. American Heart Journal, 2013, 165, 65-72.	1.2	212
7	Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet, The, 2021, 397, 199-207.	6.3	164
8	Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. European Heart Journal, 2015, 36, 3189-3198.	1.0	161
9	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	1.2	132
10	Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. EuroIntervention, 2017, 13, 432-439.	1.4	98
11	Incidence, Management, and Immediate- and Long-Term Outcomes After latrogenic Aortic Dissection During Diagnostic or Interventional Coronary Procedures. Circulation, 2015, 131, 2114-2119.	1.6	87
12	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention, 2017, 13, 459-466.	1.4	83
13	Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry. European Heart Journal, 2021, 42, 3161-3171.	1.0	82
14	3-Year Follow-Up of the Balloon Elution and Late Loss Optimization Study (BELLO). JACC: Cardiovascular Interventions, 2015, 8, 1132-1134.	1.1	74
15	A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study. International Journal of Cardiology, 2015, 184, 17-21.	0.8	51
16	Provisional vs. two-stent technique for unprotected left main coronary artery disease after ten years follow up: A propensity matched analysis. International Journal of Cardiology, 2016, 211, 37-42.	0.8	48
17	Comparison of Effectiveness and Safety of Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With Diabetes Mellitus (from the Italian Multicenter Randomized DESSERT Study). American Journal of Cardiology, 2008, 101, 1560-1566.	0.7	45
18	Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study. Journal of Neurology, 2015, 262, 459-468.	1.8	43

#	Article	IF	CITATIONS
19	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	1.1	41

Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation) Tj ETQq0 0 0 rgBT /@verlock 128Tf 50 692

21	P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 31-42.	1.4	37
22	Bivalirudin or Heparin in Patients Undergoing Invasive Management of AcuteÂCoronaryÂSyndromes. Journal of the American College of Cardiology, 2018, 71, 1231-1242.	1.2	32
23	Magmarisâ,,¢ resorbable magnesium scaffold: state-of-art review. Future Cardiology, 2019, 15, 267-279.	0.5	32
24	Multicentre experience with MGuardâ"¢ net protective stent in STâ€elevation myocardial infarction: Safety, feasibility, and impact on myocardial reperfusion. Catheterization and Cardiovascular Interventions, 2010, 75, 715-721.	0.7	31
25	Unplanned Percutaneous Coronary Revascularization After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 198-207.	1.1	30
26	Complete or incomplete coronary revascularisation in patients with myocardial infarction and multivessel disease: a propensity score analysis from the "real-life―BleeMACS (Bleeding complications) Tj E	ETQq <u>0</u> 00	rgB <u>T</u> /Overl
27	registry. EuroIntervention, 2017, 13, 407-414. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. European Journal of Preventive Cardiology, 2020, 27, 696-705.	0.8	28
28	Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e002896.	1.4	26
29	Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. International Journal of Cardiology, 2020, 301, 200-206.	0.8	26
30	What is the optimal treatment for symptomatic patients with isolated coronary myocardial bridge? A systematic review and pooled analysis. Journal of Cardiovascular Medicine, 2017, 18, 758-770.	0.6	25
31	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. European Heart Journal Supplements, 2018, 20, F1-F74.	0.0	25
32	A propensity score matched comparative study between paclitaxelâ€coated balloon and everolimusâ€eluting stents for the treatment of small coronary vessels. Catheterization and Cardiovascular Interventions, 2017, 90, 380-386.	0.7	23
33	Cardiogenic shock complicating acute myocardial infarction in the elderly: Predictors of longâ€ŧerm survival. Catheterization and Cardiovascular Interventions, 2011, 78, 505-511.	0.7	22
34	Long-Term Outcomes of Percutaneous Coronary Interventions With Stent Implantation in Patients â‰ ¤ 0 Years Old. American Journal of Cardiology, 2012, 109, 1717-1721.	0.7	22
35	Safety and efficacy of drug eluting stents in patients with spontaneous coronary artery dissection. International Journal of Cardiology, 2017, 238, 105-109.	0.8	22
36	Post-Procedural Bivalirudin Infusion atÂFull or Low Regimen in Patients WithÂAcute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 73, 758-774.	1.2	22

#	Article	IF	CITATIONS
37	Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world〕registry. Cardiology Journal, 2016, 23, 374-383.	0.5	22
38	Long-Term (≥10ÂYears) Safety of Percutaneous Treatment of Unprotected Left Main Stenosis With Drug-Eluting Stents. American Journal of Cardiology, 2016, 118, 32-39.	0.7	20
39	Acute and longâ€term outcomes after polytetrafluoroethylene or pericardium covered stenting for grade 3 coronary artery perforations: Insights from G3 AP registry. Catheterization and Cardiovascular Interventions, 2018, 92, 1247-1255.	0.7	20
40	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). American Journal of Cardiology, 2019, 123, 1610-1619.	0.7	20
41	Safety of intermediate left main stenosis revascularization deferral based on fractional flow reserve and intravascular ultrasound: A systematic review and meta-regression including 908 deferred left main stenosis from 12 studies. International Journal of Cardiology, 2018, 271, 42-48.	0.8	19
42	Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry. Thrombosis Research, 2018, 167, 142-148.	0.8	19
43	MGUard versus bAreâ€metal stents plus manual thRombectomy in STâ€elevation myocarDial infarction pAtieNts—(GUARDIAN) trial: Study design and rationale. Catheterization and Cardiovascular Interventions, 2012, 79, 1118-1126.	0.7	18
44	APpropriAteness of percutaneous Coronary interventions in patients with ischaemic HEart disease in Italy: the APACHE pilot study. BMJ Open, 2017, 7, e016909.	0.8	16
45	Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry. American Journal of Cardiovascular Drugs, 2019, 19, 381-391.	1.0	16
46	Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry. International Journal of Cardiology, 2018, 273, 29-33.	0.8	15
47	Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 536-542.	0.4	15
48	Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes. Catheterization and Cardiovascular Interventions, 2020, 96, 1-9.	0.7	15
49	One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). EuroIntervention, 2017, 13, 424-431.	1.4	15
50	Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study. International Journal of Cardiology, 2018, 250, 80-85.	0.8	14
51	P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 196-205.	1.4	14
52	Percutaneous left main coronary disease treatment without onâ€site surgery backâ€up in patients with acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2012, 79, 979-987.	0.7	13
53	Feasibility of carotid artery stenting with double cerebral embolic protection in highâ€risk patients. Catheterization and Cardiovascular Interventions, 2016, 87, 432-437.	0.7	13

Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAIn or) Tj ETQq0 0 0 rgBT @verlock 110 Tf 50 52

#	Article	IF	CITATIONS
55	Clinical Outcomes Following Percutaneous Coronary Intervention With Drugâ€ <scp>E</scp> luting Stents Versus Bare Metal Stents in Patients on Chronic Hemodialysis. Journal of Interventional Cardiology, 2013, 26, 351-358.	0.5	12
56	Current practice of transradial approach for coronary procedures: A survey by the Italian Society of Interventional Cardiology (SICI-GISE) and the Italian Radial Club. Cardiovascular Revascularization Medicine, 2017, 18, 154-159.	0.3	12
57	Radial Versus Femoral Access for the Treatment of LeftÂMain Lesion in the Era of Second-Generation Drug-Eluting Stents. American Journal of Cardiology, 2017, 120, 33-39.	0.7	12
58	Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients – results from the BELLO (balloon elution and late loss) Tj ETQq0 0 0 rgBT	/ Ov.e rlock	102f 50 617
59	First reported case of magnesiumâ€made bioresorbable scaffold to treat spontaneous left anterior descending coronary artery dissection. Catheterization and Cardiovascular Interventions, 2017, 90, 768-772.	0.7	12
60	Primary angioplasty and routine utilization of thrombus aspiration devices: feasibility and results in a consecutive series of 486 patients. Journal of Cardiovascular Medicine, 2007, 8, 258-264.	0.6	11
61	Sirolimus-Eluting Magnesium Resorbable Scaffold Implantation in Patients with Acute Myocardial Infarction. Cardiology, 2019, 142, 93-96.	0.6	11
62	ls percutaneous coronary intervention of unprotected left main coronary artery via transradial approach feasible for skilled transfemoral operators? Initial experience in an unselected population. Cardiovascular Revascularization Medicine, 2013, 14, 193-196.	0.3	10
63	Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock. Circulation Journal, 2015, 79, 1568-1574.	0.7	10
64	Impact of thrombus aspiration during primary percutaneous coronary intervention in cardiogenic shock complicating ST-segment elevation myocardial infarction. Cardiovascular Revascularization Medicine, 2013, 14, 307-310.	0.3	9
65	Primary percutaneous coronary intervention without on-site cardiac surgery backup in unselected patients with ST-segment-Elevation Myocardial Infarction: The RIvoli ST-segment Elevation Myocardial Infarction (RISTEMI) registry. Cardiovascular Revascularization Medicine, 2013, 14, 9-13.	0.3	8
66	Incidence, Management, Immediate and Long-Term Outcome of Guidewire and Device Related Grade III Coronary Perforations (from G3CAP - Cardiogroup VI Registry). American Journal of Cardiology, 2021,	0.7	8

66	Coronary Perforations (from G3CAP - Cardiogroup VI Registry). American Journal of Cardiology, 2021, 143, 37-45.	0.7	8
67	Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study. Minerva Cardioangiologica, 2019, 67, 94-101.	1.2	8
68	Trends of percutaneous coronary intervention in Italy in the last 10 years. Journal of Cardiovascular Medicine, 2017, 18, 170-177.	0.6	7
69	Planned angiographic control versus clinical followâ€up for patients with unprotected left main stem stenosis treated with second generation drugâ€eluting stents: A propensity score with matching analysis from the FAILS (failure in left main with second generation stentsâ€Cardiogroup III Study). Catheterization and Cardiovascular Interventions. 2018. 92. E271-E277.	0.7	7
70	Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. IJC Heart and Vasculature, 2019, 22, 39-45.	0.6	7
71	Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries. Cardiovascular Drugs and Therapy, 2021, 35, 1171-1182.	1.3	7
72	Perforation of the sinus of Valsalva by guiding catheter during the percutaneous coronary intervention via the right transradial approach: A very unusual complication. Catheterization and	0.7	6

intervention via the right transradial approach: A very unusual complication. Catheterization and Cardiovascular Interventions, 2011, 78, 888-891. 72

1.1

4

#	Article	IF	CITATIONS
73	Importance of Close Surveillance of Patients With Conservatively Managed Spontaneous Coronary Artery Dissection. JACC: Cardiovascular Interventions, 2018, 11, e87-e89.	1.1	6
74	Spontaneous coronary artery dissection treated with magnesiumâ€made bioresorbable scaffold: 1â€Year angiographic and optical coherence tomography followâ€up. Catheterization and Cardiovascular Interventions, 2019, 93, E130-E133.	0.7	6
75	Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. Catheterization and Cardiovascular Interventions, 2021, 97, E227-E236.	0.7	6
76	Utilidad de la puntuación PARIS para evaluar el equilibrio isquémico-hemorrágico con ticagrelor y prasugrel tras un sÃndrome coronario agudo. Revista Espanola De Cardiologia, 2019, 72, 215-223.	0.6	6
77	Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. European Heart Journal Cardiovascular Imaging. 2019. 20. 1418-1428.	0.5	5
78	Aspirin desensitization procedures in aspirin intolerant patients: a neglected topic in the ESC 2019 Chronic Coronary Syndrome guidelines. European Heart Journal, 2020, 41, 482-482.	1.0	5
79	Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from) Tj ETQq1	1 0.784314 0.7	rg&T /Overloo
80	Is Aspirin Still the Cornerstone of Antiplatelet Therapy in Patients With Coronary Artery Disease? An Historical and Practical Narrative Review. Hospital Practices and Research, 2017, 2, 94-101.	0.1	5
81	PK Papyrus coronary stent system: the ultrathin struts polyurethane-covered stent. Future Cardiology, 2020, 16, 405-411.	0.5	5
82	Impact of stent thickness on clinical outcomes in small vessel and bifurcation lesions: a RAIN-CARDIOGROUP VII sub-study. Journal of Cardiovascular Medicine, 2021, 22, 20-25.	0.6	5
83	Unprotected Left Main Coronary Artery Disease: Outcomes of Treatment With Second-Generation Drug-Eluting Stents - Insight From the FAILS-2 Study. Journal of Invasive Cardiology, 2018, 30, 283-288.	0.4	5
84	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. Journal of the American Heart Association, 2022, 11, e022320.	1.6	5
85	Severe multivessel coronary spasm after sirolimus-eluting stent implantation. Journal of Cardiovascular Medicine, 2009, 10, 485-488.	0.6	4
86	Spontaneous coronary artery dissection treated with biovascular scaffolds guided by intravascular ultrasounds imaging. Cardiovascular Intervention and Therapeutics, 2017, 32, 186-189.	1.2	4
87	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. International Journal of Cardiology, 2019, 280, 30-37.	0.8	4
88	Prediction of longâ€ŧerm patient outcome after contemporary left main stenting using the SYNTAX and SYNTAX II scores: A comparative analysis from the FAILâ€II multicenter registry (failure in left main study) Tj ET	Qq0 0 0 rgB	T /Qverlock 1
89	2020, 96, E17-E26. Cardiac Computed Tomography Angiography Follow-Up of Resorbable Magnesium Scaffolds. Cardiovascular Revascularization Medicine, 2021, 29, 18-21.	0.3	4

90 Worldwide SurvEy on Clinical and Anatomical Factors Driving the Choice of Transcatheter Aortic Valve pRostheses. Frontiers in Cardiovascular Medicine, 2020, 7, 38.

#	Article	IF	CITATIONS
91	Quantitative flow ratio as a new tool for angiography-based physiological evaluation of coronary artery disease: a review. Future Cardiology, 2021, 17, 1435-1452.	0.5	4
92	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1170-1179.	0.4	4
93	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting ProlongedÂBivalirudin Infusion. JACC: Cardiovascular Imaging, 2019, 12, 934-936.	2.3	3
94	Two-year clinical outcomes of the "Italian diffuse/multivessel disease absorb prospective registry― (IT-DISAPPEARS). International Journal of Cardiology, 2019, 290, 21-26.	0.8	3
95	Lack of implementation of guidelines recommendations for coronary revascularization in stable patients with complex disease is associated with high rates of incomplete revascularization. Heart and Vessels, 2020, 35, 30-37.	0.5	3
96	Safety and efficacy of polymerâ€free biolimusâ€eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. Catheterization and Cardiovascular Interventions, 2020, 95, 522-529.	0.7	3
97	Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. Minerva Cardiology and Angiology, 2021, 69, 408-416.	0.4	3
98	Italy: coronary and structural heart interventions from 2010 to 2015. EuroIntervention, 2017, 13, Z37-Z41.	1.4	3
99	Unintended stent removal during fractured-guidewire removal in emergency angioplasty. Journal of Cardiovascular Medicine, 2009, 10, 885-886.	0.6	2
100	Setting up a multidisciplinary program of carotid artery stenting in a community hospital: Initial experience of 277 patients. International Journal of Cardiology, 2015, 179, 17-19.	0.8	2
101	Temporal changes in the current practice of primary angioplasty: a real life experience of a single high-volume center. Cardiovascular Revascularization Medicine, 2016, 17, 5-9.	0.3	2
102	Role of Invasive and Non-invasive Imaging Tools in the Diagnosis and Optimal Treatment of Patients with Spontaneous Coronary Artery Dissection. Current Cardiology Reports, 2019, 21, 122.	1.3	2
103	Assessment of residual thrombus burden in patients with STâ€segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Tj ETQq1 1 ().784314 rgB 0.7	T /Overlock 1
104	Anatomical and functional healing after resorbable magnesium scaffold implantation in human coronary vessels: A combined optical coherence tomography and quantitative flow ratio analysis. Catheterization and Cardiovascular Interventions, 2021, 98, 1038-1046.	0.7	2
105	Acute Interventional Management of Spontaneous Coronary Artery Dissection: Case Series and Literature Review. International Cardiovascular Forum Journal, 0, 15, .	1.1	2
106	New drug-eluting stent implantation for recalcitrant in-stent restenosis treated with drug-eluting stents. the Stent-in-Stent Cube (SISÂ ³) registry. Journal of Invasive Cardiology, 2011, 23, 365-8.	0.4	2
107	Recurrent restenosis after implantation of sirolimus-eluting stents in aorto-ostial lesions: successful treatment with polytetrafluoroethylene-covered stents. Journal of Cardiovascular Medicine, 2008, 9, 201-204.	0.6	1
108	Immediate and long-term results of treatment of complex lesions of the left anterior descending coronary artery involving a large diagonal branch with drug-eluting stents. Journal of Cardiovascular Medicine, 2008, 9, 1088-1094.	0.6	1

#	Article	IF	CITATIONS
109	Chronic total occlusion treatment as a health insurance. Journal of Cardiovascular Medicine, 2013, 14, 899-901.	0.6	1
110	Biolimus-Eluting StenT For de-novo coRonary artery dlsease in patiENts with Diabetes mellituS. Journal of Cardiovascular Medicine, 2016, 17, 729-735.	0.6	1
111	Left Ventricular Free-Wall Rupture. New England Journal of Medicine, 2017, 377, e13.	13.9	1
112	Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel. Revista Espanola De Cardiologia (English Ed), 2019, 72, 298-304.	0.4	1
113	ImpaCt of an Optimal Implantation Strategy on Absorb Long-Term Outcomes: The CIAO Registry. Cardiovascular Revascularization Medicine, 2021, 30, 1-8.	0.3	1
114	Realâ€world reasons and outcomes for 1â€month versus longer dual antiplatelet therapy strategies with a polymerâ€free BIOLIMUS A9â€coated stent. Catheterization and Cardiovascular Interventions, 2020, 96, E248-E256.	0.7	1
115	Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial) Tj ETQq1 1 1143-1150.	0.784314 rg 0.7	gBT_/Overlo <mark>ck</mark>
116	Choice of vascular access in primary PCI. Minerva Cardiology and Angiology, 2018, 66, 400-410.	0.4	1
117	Angiographic control versus ischaemia-driven management of patients undergoing percutaneous revascularisation of the unprotected left main coronary artery with second-generation drug-eluting stents: rationale and design of the PULSE trial. Open Heart, 2020, 7, e001253.	0.9	1
118	Thrombectomy Pretreatment Versus Standard Stenting in ST-Elevation Myocardial Infarction: Does the Debate Still Not EXPIRe?. American Journal of Cardiology, 2011, 107, 1100.	0.7	0
119	Antegrade trapping balloon technique to increase support in percutaneous treatment of â€`uncrossable' lesions. Journal of Cardiovascular Medicine, 2013, 14, 247-248.	0.6	0
120	TCT-61 Gender-related Differences in 30-day Mortality Among Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. Journal of the American College of Cardiology, 2014, 64, B18.	1.2	0
121	TCT-353 Acute and mid-term performance of Magmaris Bioresorbable Scaffold implantation in complex lesions: a multicenter experience Journal of the American College of Cardiology, 2018, 72, B144.	1.2	0
122	TCT-704 Feasibility of overlapped Magnesium-made bioresorbable scaffold implantation in long lesions: results from the multicenter italian registry (MAGIC). Journal of the American College of Cardiology, 2018, 72, B281-B282.	1.2	0
123	TCT-470 Acute Management of Patients With Spontaneous Coronary Artery Dissection: The DISCO (DIssezioni Spontanee COronariche) Italian Registry. Journal of the American College of Cardiology, 2019, 74, B465.	1.2	0
124	One-Year OCT Follow-Up Results of Overlapping Resorbable Magnesium Scaffolds: Mind the Gap!. Cardiovascular Revascularization Medicine, 2020, 21, 126-129.	0.3	0
125	One Year of OCT Follow-Up After Implantation of Three Different BRS in the Same Coronary Artery. Cardiovascular Revascularization Medicine, 2020, 21, 121-122.	0.3	0
126	Characteristics and outcomes of elderly patients undergoing carotid stenting: Experience of a highâ€volume interventional cardiology center. Catheterization and Cardiovascular Interventions, 2022, 99, 853-859.	0.7	0